# Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

> **NCT05263947** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 35 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Bevacizumab
- Tyrosine Kinase Inhibitor
- EGFR L858R

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT05263947
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263947, "Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05263947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*